

Provincial Retinal Diseases Treatment Program (PRDTP)

Quality Update: December, 2023

In January 2023, the PRDTP established a Program Quality Subcommittee (QSC). This group is comprised of retinal specialists, along with PHSA and Ministry representation, and supporting expertise as required. A key early task of the group was to create a Program Quality Framework. This Framework follows the seven [Quality Dimensions](#) established by Health Quality BC to develop clear PRDTP Quality Goals that framed a Quality Action Plan for the year ahead.

Table 1. PRDTP Quality Framework

Health Quality BC Dimension	PRDTP Quality Goals
1. Respect/ Cultural Safety	<ul style="list-style-type: none"> Patients and their families experience care that feels safe, respectful, and kind in a healthcare system that is respectful of individual's needs and context.
2. Safety	<ul style="list-style-type: none"> There is a culture of no-blame and trust, encouraging teams, clinicians, and patients to speak up with any safety concerns.
3. Accessibility	<ul style="list-style-type: none"> The process for referral and access for patients is timely and straightforward.
4. Appropriateness	<ul style="list-style-type: none"> The Program provides the right treatment for the right patient, at the right time, every time.
5. Effectiveness	<ul style="list-style-type: none"> Patient outcomes following treatment are positive, and the team uses data to understand and improve the patient experience.
6. Equity	<ul style="list-style-type: none"> Each patient within BC receives equitable care, no matter their personal circumstance.
7. Efficiency	<ul style="list-style-type: none"> The program delivers streamlined and efficient processes to support patient care

Within this framework, the QSC has had a busy and effective year. Examples of this work included:

- Selecting and implementing a designated intravitreal syringe for planned introduction in 2024.
- Completion of the first phase of developing PRDTP Clinical Guidelines.
- Improvements to the PRDTP database in terms of data integrity, quality, and reporting.
- Follow up on the Quality Review regarding glaucoma-related outcomes and anti-VEGF treatment. Incidence of glaucoma-related outcomes remain stable and consistent with data reported in 2020.
- Creation of an initial set of PRDTP indicators, including development of new quality metrics to capture visual acuity outcomes for patients.
- Piloting of a Patient Experience Questionnaire in two clinics, with plans to expand this survey across all clinics.
- Completion of a PRDTP patient access review across the province, meeting with regional health authority leads to collaborate on strategies for improvement as applicable.